News

The new approach will ensure that high-impact devices, diagnostics and digital tools recommended by NICE, that meet the most urgent needs, are nationally reimbursed and made available across the NHS - ...
The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...
In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented ...
New guideline will help cut falls and related hospital admissions for older and at-risk people. Personalised assessments that consider factors including the hazards in a person’s home, and their ...
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.. Last reviewed: 25 June 2025 Next review: This guidance will be reviewed if ...
Your responsibility. This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected ...
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.. Last reviewed: 18 June 2025 Next review: This guidance will be reviewed if there ...
Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies.. Last reviewed: 24 June 2025 Next review: ...
This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on ...
This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.
Groundbreaking one-off gene therapy approved for severe sickle cell disease. People in England with severe sickle cell disease will be among the first to receive treatment using revolutionary CRISPR ...